Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

PubWeight™: 9.20‹?› | Rank: Top 0.1%

🔗 View Article (PMC 2963075)

Published in N Engl J Med on October 15, 2008

Authors

Yujin Hoshida1, Augusto Villanueva, Masahiro Kobayashi, Judit Peix, Derek Y Chiang, Amy Camargo, Supriya Gupta, Jamie Moore, Matthew J Wrobel, Jim Lerner, Michael Reich, Jennifer A Chan, Jonathan N Glickman, Kenji Ikeda, Masaji Hashimoto, Goro Watanabe, Maria G Daidone, Sasan Roayaie, Myron Schwartz, Swan Thung, Helga B Salvesen, Stacey Gabriel, Vincenzo Mazzaferro, Jordi Bruix, Scott L Friedman, Hiromitsu Kumada, Josep M Llovet, Todd R Golub

Author Affiliations

1: Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.

Articles citing this

(truncated to the top 100)

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98

Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut (2012) 3.67

DNA damage-mediated induction of a chemoresistant niche. Cell (2010) 2.94

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59

Bayesian method to predict individual SNP genotypes from gene expression data. Nat Genet (2012) 2.50

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46

Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40

Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40

Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36

Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One (2009) 2.21

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13

S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med (2010) 2.13

From single cells to deep phenotypes in cancer. Nat Biotechnol (2012) 2.12

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08

The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol (2010) 2.07

Cancer stem cells in the development of liver cancer. J Clin Invest (2013) 2.06

Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res (2009) 1.91

3'-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS One (2010) 1.91

Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91

Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.87

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86

Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One (2010) 1.84

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72

Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68

Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One (2010) 1.65

Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol (2009) 1.60

Recurrence of hepatocellular carcinoma. N Engl J Med (2008) 1.60

Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59

Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritis. J Mol Diagn (2011) 1.57

Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol (2015) 1.54

The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int (2012) 1.53

JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res (2012) 1.52

MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One (2011) 1.50

Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer (2009) 1.49

k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. Pharmacogenomics J (2010) 1.46

New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46

Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn (2010) 1.44

Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (2013) 1.41

Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40

mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40

The clinical potential of microRNAs. J Hematol Oncol (2010) 1.39

Sorafenib: where do we go from here? Hepatology (2010) 1.38

Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett (2012) 1.36

Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33

Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32

Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27

Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One (2011) 1.26

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res (2009) 1.26

Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer (2012) 1.24

Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut (2012) 1.22

A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol (2010) 1.18

Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol (2009) 1.17

Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One (2014) 1.17

Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17

Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16

Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16

Current management of hepatocellular carcinoma. World J Gastroenterol (2014) 1.14

The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst (2011) 1.14

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14

ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia (2010) 1.14

Analyses and interpretation of whole-genome gene expression from formalin-fixed paraffin-embedded tissue: an illustration with breast cancer tissues. BMC Genomics (2010) 1.13

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol (2012) 1.10

Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol (2009) 1.10

The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res (2011) 1.10

Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10

Detection call algorithms for high-throughput gene expression microarray data. Brief Bioinform (2009) 1.09

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology (2011) 1.07

JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer (2009) 1.07

Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One (2013) 1.06

Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 1.06

Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06

Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05

Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05

The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol (2013) 1.04

HCC: current surgical treatment concepts. Langenbecks Arch Surg (2012) 1.03

Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver (2013) 1.03

SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer (2014) 1.03

Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res (2010) 1.03

Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol (2012) 1.03

Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol (2014) 1.03

Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res (2009) 1.02

Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Transl Oncol (2014) 1.02

High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget (2014) 1.01

Articles cited by this

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

GenePattern 2.0. Nat Genet (2006) 29.07

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26

Hepatocellular carcinoma. Lancet (2003) 22.54

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28

A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res (2004) 4.19

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42

Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol (2004) 3.04

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38

Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. J Mol Diagn (2007) 2.04

Articles by these authors

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51

A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60

GenePattern 2.0. Nat Genet (2006) 29.07

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99

Hepatocellular carcinoma. Lancet (2003) 22.54

A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Hepatocellular carcinoma. Lancet (2012) 18.09

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41

Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28

Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12

The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13

Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46

Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28

Calibrating a coalescent simulation of human genome sequence variation. Genome Res (2005) 15.04

The genomic complexity of primary human prostate cancer. Nature (2011) 14.06

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79

New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76

Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10

Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet (2008) 12.07

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92

TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69

Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87

A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81

MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature (2012) 8.91

The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (2013) 8.53

XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43

Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell (2007) 8.42

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38

Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44

Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14

Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03

Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci U S A (2003) 6.87

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75